Trial Profile

Objective Confirmation of thе Anti-ischemic Effectiveness of Trimetazidine 80mg Once Daily in Patients With Stable Angina Who Had a History of Myocardial Infarction (METHOD)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 26 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trimetazidine (Primary)
Indications Angina pectoris; Myocardial ischaemia
Focus Therapeutic Use
Acronyms METHOD
Sponsors Servier Russia

Most Recent Events

03 Jun 2024 Primary endpoint has been met. (mean change in left ventricular global longitudinal strain (LV GLS) at visit 2 ( 6 months) compared to baseline (BL), as per Results presented at the 33rd European meeting on hypertension and cardiovascular protection
03 Jun 2024 Results presented at the 33rd European meeting on hypertension and cardiovascular protection
17 Apr 2024 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com